LIMN
Liminatus Pharma, Inc. Class A Common Stock
NASDAQ · Healthcare · Biotechnology · US
$3.71
+0.27%Institutional positioning
13F filings over the trailing two quarters
New 6Increased 5Reduced 5Sold out 13
| Filer | Action | Shares | Filed |
|---|---|---|---|
| CITADEL ADVISORS LLC | Increased | 677,518 | May 15, 2026 |
| Cygnus Capital Advisors, LLC | New Position | 350,000 | May 13, 2026 |
| Cygnus Capital Advisors, LLC | Reduced | 329,333 | Sep 3, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Increased | 117,783 | May 15, 2026 |
| JANE STREET GROUP, LLC | New Position | 71,318 | May 12, 2026 |
| CITADEL ADVISORS LLC | Reduced | 56,089 | Sep 2, 2026 |
| UBS GROUP AG | Increased | 54,578 | May 5, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 50,440 | May 15, 2026 |
| VANGUARD PERSONALIZED INDEXING MANAGEMENT, LLC | New Position | 34,706 | May 14, 2026 |
| VIRTU FINANCIAL LLC | New Position | 27,468 | May 14, 2026 |
| VANGUARD FIDUCIARY TRUST CO | New Position | 22,984 | May 8, 2026 |
| TWO SIGMA SECURITIES, LLC | Increased | 22,039 | May 15, 2026 |
| STATE STREET CORP | Unchanged | 19,000 | May 15, 2026 |
| BLACKROCK, INC. | Reduced | 13,254 | May 13, 2026 |
| TOWER RESEARCH CAPITAL LLC (TRC) | Reduced | 7,567 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings